9 results on '"Capello, Daniela"'
Search Results
2. Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes.
- Author
-
Ferrero S, Capello D, Svaldi M, Boi M, Gatti D, Drandi D, Rossi D, Barbiero S, Mantoan B, Mantella E, Zanni M, Ghione P, Larocca A, Passera R, Bertoni F, Gattei V, Forconi F, Laurenti L, Del Poeta G, Marasca R, Cortelazzo S, Gaidano G, Palumbo A, Boccadoro M, and Ladetto M
- Subjects
- B-Lymphocytes immunology, B-Lymphocytes pathology, Complementarity Determining Regions chemistry, Complementarity Determining Regions immunology, Data Mining, Databases, Nucleic Acid, Humans, Multigene Family immunology, Multiple Myeloma immunology, Myeloma Proteins chemistry, Myeloma Proteins immunology, Sequence Analysis, DNA, Somatic Hypermutation, Immunoglobulin immunology, Complementarity Determining Regions genetics, Genes, Immunoglobulin Heavy Chain immunology, Multiple Myeloma genetics, Myeloma Proteins genetics
- Abstract
Background: Characterization of the immunoglobulin gene repertoire has improved our understanding of the immunopathogenesis of lymphoid tumors. Early B-lymphocyte precursors of multiple myeloma are known to exist and might be susceptible to antigenic drive., Design and Methods: To verify this hypothesis, we collected a database of 345 fully readable multiple myeloma immunoglobulin sequences. We characterized the immunoglobulin repertoire, analyzed the somatic hypermutation load, and investigated for stereotyped receptor clusters., Results: Compared to the normal immunoglobulin repertoire, multiple myeloma displayed only modest differences involving only a few genes, showing that the myeloma immunoglobulin repertoire is the least skewed among mature B-cell tumors. Median somatic hypermutation load was 7.8%; median length of complementarity determining-region 3 was 15.5 amino acids. Clustering analysis showed the absence of myeloma specific clusters and no similarity with published chronic lymphocytic leukemia or lymphoma subsets., Conclusions: Analysis of multiple myeloma immunoglobulin repertoire does not support a pathogenetic role for antigen selection in this tumor.
- Published
- 2012
- Full Text
- View/download PDF
3. Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma.
- Author
-
Zibellini S, Capello D, Forconi F, Marcatili P, Rossi D, Rattotti S, Franceschetti S, Sozzi E, Cencini E, Marasca R, Baldini L, Tucci A, Bertoni F, Passamonti F, Orlandi E, Varettoni M, Merli M, Rizzi S, Gattei V, Tramontano A, Paulli M, Gaidano G, and Arcaini L
- Subjects
- Adult, Aged, Aged, 80 and over, Antigens, Epitopes, Gene Rearrangement, Humans, Immunoglobulin Heavy Chains genetics, Lymphoma, B-Cell, Marginal Zone immunology, Splenic Neoplasms immunology, Lymphoma, B-Cell, Marginal Zone etiology, Receptors, Antigen, B-Cell immunology, Splenic Neoplasms etiology
- Abstract
Antigen stimulation may be important for splenic marginal zone lymphoma pathogenesis. To address this hypothesis, the occurrence of stereotyped B-cell receptors was investigated in 133 SMZL (26 HCV+) compared with 4,414 HCDR3 sequences from public databases. Sixteen SMZL (12%) showed stereotyped BCR; 7 of 86 (8%) SMZL sequences retrieved from public databases also belonged to stereotyped HCDR3 subsets. Three categories of subsets were identified: i) "SMZL-specific subsets" (n=5), composed only of 12 SMZL (9 HCV-from our series); ii) "Non-Hodgkin's lymphoma-like subsets" (n=5), comprising 5 SMZL (4 from our series) clustering with other indolent lymphomas; iii) "CLL-like subsets" (n=6), comprising 6 SMZL (3 from our series) that belonged to known CLL subsets (n=4) or clustered with public CLL sequences. Immunoglobulin 3D modeling of 3 subsets revealed similarities in antigen binding regions not limited to HCDR3. Overall, data suggest that the pathogenesis of splenic marginal zone lymphoma may involve also HCV-unrelated epitopes or an antigenic trigger common to other indolent lymphomas.
- Published
- 2010
- Full Text
- View/download PDF
4. CD49d expression is an independent risk factor of progressive disease in early stage chronic lymphocytic leukemia.
- Author
-
Rossi D, Zucchetto A, Rossi FM, Capello D, Cerri M, Deambrogi C, Cresta S, Rasi S, De Paoli L, Bodoni CL, Bulian P, Del Poeta G, Ladetto M, Gattei V, and Gaidano G
- Subjects
- Aged, Biomarkers, Tumor blood, Female, Humans, Male, Neoplasm Staging, Risk Factors, Survival Rate, Time Factors, Disease Progression, Integrin alpha4 blood, Leukemia, Lymphocytic, Chronic, B-Cell blood, Leukemia, Lymphocytic, Chronic, B-Cell pathology
- Abstract
Identification of prognosticators for Binet A chronic lymphocytic leukemia is important for selecting patients with dismal prognosis. We analyzed CD49d expression in 140 consecutive Binet A chronic lymphocytic leukemia. At diagnosis, CD49d >or=30% (54/140, 38.6%) associated with proliferation markers, namely CD38 >or=30% (p=3.9 x 10(-6)), LDH (p=0.007) and beta2-microglobulin (p=0.020). Univariate log-rank analysis identified CD49d >or=30% as a risk factor of treatment free survival (p=8.3 x 10(-5)), time to progression to a more advanced stage (p=4.7 x 10(-4)), and time to lymphocyte doubling (p=0.009). Multivariate analysis selected CD49d >or=30% as an independent treatment free survival predictor after adjustment for biological (HR 2.28; 95% CI 1.71-4.45, p=0.015) and both biological and clinical variables analyzed together (HR 3.33, 95% CI 1.61-6.90, p=0.001). Within Binet A subgroups harboring favorable biological variables (IGHV homology <98%, favorable karyotype, CD38 <30%, ZAP70 <20%) or clinical variables, CD49d >or=30% consistently identified a subset of patients with short treatment free survival. Our observations indicate CD49d >or=30% as a new marker for the initial prognostic assessment of Binet A chronic lymphocytic leukemia.
- Published
- 2008
- Full Text
- View/download PDF
5. Molecular analysis of immunoglobulin variable genes in human immunodeficiency virus-related non-Hodgkin's lymphoma reveals implications for disease pathogenesis and histogenesis.
- Author
-
Capello D, Martini M, Gloghini A, Cerri M, Rasi S, Deambrogi C, Rossi D, Spina M, Tirelli U, Larocca LM, Carbone A, and Gaidano G
- Subjects
- Bathing Beaches, Burkitt Lymphoma genetics, Burkitt Lymphoma immunology, Burkitt Lymphoma pathology, Gene Amplification, Gene Rearrangement, HIV Infections immunology, HIV Infections pathology, Humans, Lymphoma, Non-Hodgkin pathology, Polymerase Chain Reaction, Receptors, Antigen, B-Cell genetics, Somatic Hypermutation, Immunoglobulin genetics, HIV Infections complications, Immunoglobulin Variable Region genetics, Lymphoma, Non-Hodgkin genetics, Lymphoma, Non-Hodgkin immunology
- Abstract
Background: Human immunodeficiency virus (HIV)-related non-Hodgkin's lymphomas (HIV-NHL) are heterogeneous and associated with distinct molecular pathways. Analysis of immunoglobulin variable genes (IGV) may provide insights into the pathogenesis and histogenesis of HIV-NHL., Design and Methods: IGV rearrangements were amplified from genomic DNA by polymerase chain reaction and directly sequenced in 87 cases of HIV-NHL (17 Burkitt/Burkitt-like lymphomas, 38 diffuse large B-cell lymphomas, and 32 primary central nervous system lymphomas)., Results: A skewed IGHV repertoire in specific HIV-NHL clinico-pathological categories was observed. Systemic HIV-diffuse large B-cell lymphomas displayed underrepresentation of the IGHV3 family (11/38, 28.9%; p=0.0047) and, in particular, of the IGHV3-23 gene (0/38; p<0.001). These same cases were also characterized by significant overrepresentation of the IGHV4 family (18/38; 47.4%; p=0.0044) and, in particular, of the IGHV4-34 gene (10/38; 26.3%; p=0.003). HIV-primary central nervous system lymphomas displayed a preferential usage of IGLV6-57, with stereotyped B-cell receptor in two cases. Somatic hypermutation of IGHV genes was detected in 81/87 (93.1%) HIV-NHL. Unmutated cases were restricted to six HIV-primary central nervous system lymphomas with immunoblastic plasmacytoid morphology. A mutational profile suggesting a tendency to maintain antigen binding and antigen selection was observed in more than 50% of the cases of IGV mutated HIV-NHL., Conclusions: Our data show evidence of a skewed IGHV repertoire in specific HIV-NHL categories and suggest B-cell receptor restriction in some HIV-primary central nervous system lymphomas. The heterogeneous representation of IGHV genes in HIV-NHL may be related to specific pathways of antigen stimulation, or to differences in host's immune dysregulation and lymphoma histogenesis.
- Published
- 2008
- Full Text
- View/download PDF
6. Aberrant somatic hypermutation in transformation of follicular lymphoma and chronic lymphocytic leukemia to diffuse large B-cell lymphoma.
- Author
-
Rossi D, Berra E, Cerri M, Deambrogi C, Barbieri C, Franceschetti S, Lunghi M, Conconi A, Paulli M, Matolcsy A, Pasqualucci L, Capello D, and Gaidano G
- Subjects
- Gene Frequency, Humans, Cell Transformation, Neoplastic genetics, Cell Transformation, Neoplastic pathology, Gene Rearrangement, B-Lymphocyte, Leukemia, Lymphocytic, Chronic, B-Cell genetics, Lymphoma, B-Cell genetics, Lymphoma, Follicular genetics, Somatic Hypermutation, Immunoglobulin genetics
- Abstract
The molecular mechanisms involved in histologic transformation of follicular lymphoma (FL) and B-chronic lymphocytic leukemia (B-CLL) to diffuse large B-cell lymphoma (DLBCL) are heterogeneous and largely unknown. Here we explored whether aberrant somatic hypermutation, leading to the acquisition of new mutations in PIM-1, PAX-5, RhoH/TTF and c-MYC genes, is involved in transformation from FL or B-CLL to DLBCL. Eighteen sequential pairs of FL/DLBCL (n=9) and B-CLL/DLBCL (n=9) were investigated. Our findings demonstrate that acquisition of novel mutations due to aberrant somatic hypermutation was associated with DLBCL transformation in 5/9 (55.5%) cases of FL and 2/9 (22.2%) cases of B-CLL.
- Published
- 2006
7. Aberrant promoter methylation of multiple genes throughout the clinico-pathologic spectrum of B-cell neoplasia.
- Author
-
Rossi D, Capello D, Gloghini A, Franceschetti S, Paulli M, Bhatia K, Saglio G, Vitolo U, Pileri SA, Esteller M, Carbone A, and Gaidano G
- Subjects
- Acyltransferases genetics, Aneuploidy, Apoptosis genetics, Apoptosis Regulatory Proteins, Blast Crisis genetics, Calcium-Calmodulin-Dependent Protein Kinases genetics, Caspase 8, Caspases genetics, Cell Cycle genetics, DNA Repair genetics, DNA-Binding Proteins genetics, Death-Associated Protein Kinases, Disease Progression, Follow-Up Studies, Genes, Tumor Suppressor, Humans, Inactivation, Metabolic genetics, Leukemia, B-Cell classification, Leukemia, B-Cell pathology, Lymphoma, B-Cell classification, Lymphoma, B-Cell pathology, Nuclear Proteins genetics, O(6)-Methylguanine-DNA Methyltransferase genetics, Promoter Regions, Genetic genetics, Tumor Protein p73, Tumor Suppressor Proteins, CpG Islands, DNA Methylation, Gene Silencing, Leukemia, B-Cell genetics, Lymphoma, B-Cell genetics
- Abstract
Background and Objectives: Aberrant promoter methylation targets CpG islands causing gene silencing. We explored aberrant promoter methylation of genes potentially involved in B-cell malignancies and encoding proteins implicated in DNA repair (O6-methylguanine-DNA methyltransferase, MGMT), detoxification of environmental xenobiotics (glutathione S-transferase P1, GSTP1), apoptosis regulation (death associated protein kinase, DAP-k and caspase 8, CASP8) and cell cycle control (p73)., Design and Methods: Three hundred and seventeen B-cell malignancies were investigated by methylation-specific polymerase chain reaction (MSP) of MGMT, GSTP1, DAP-k, CASP8 and p73 genes. In selected cases, MSP results were matched to protein expression studies by immunohistochemistry or Western blotting., Results: DAP-k promoter methylation occurred at highest frequency in follicular lymphoma (85.0%) and MALT-lymphoma (72.2%). MGMT methylation targeted both precursor B-cell neoplasia (23.8%) and mature B-cell tumors (27.6%). GSTP1 methylation was commonest in hairy cell leukemia (75.0%), follicular lymphoma (55.5%), Burkitt s lymphoma (52.0%), and MALT lymphoma (50.0%). Methylation of p73 and CASP8 was rare or absent. DAP-k and MGMT methylation caused absent protein expression., Interpretation and Conclusions: Methylation of MGMT, DAP-k and GSTP1 represents a major pathogenetic event in several B-cell malignancies. In follicular lymphoma and MALT lymphoma, frequent inactivation of the apoptosis extrinsic pathway through DAP-k methylation may reinforce the survival advantage already conferred by deregulation of the intrinsic apoptotic pathway. Inactivation of GSTP1 in gastric MALT lymphoma represents an additional mechanism favoring accumulation of reactive oxygen species and lymphomagenesis. Finally, the frequency of GSTP1 aberrant methylation in diffuse large B-cell lymphoma prompts studies aimed at verifying the prognostic impact of this epigenetic lesion in these lymphomas.
- Published
- 2004
8. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas apoptosis in Burkitt's lymphomas with loss of multiple pro-apoptotic proteins.
- Author
-
Hussain A, Doucet JP, Gutiérrez M, Ahmad M, Al-Hussein K, Capello D, Gaidano G, and Bhatia K
- Subjects
- Apoptosis Regulatory Proteins, Burkitt Lymphoma etiology, Burkitt Lymphoma metabolism, Caspases metabolism, Humans, Membrane Glycoproteins physiology, Proto-Oncogene Proteins c-bcl-2 metabolism, Receptors, Tumor Necrosis Factor analysis, TNF-Related Apoptosis-Inducing Ligand, Tumor Cells, Cultured, Tumor Necrosis Factor-alpha physiology, fas Receptor physiology, Apoptosis, Burkitt Lymphoma pathology, Membrane Glycoproteins metabolism, Tumor Necrosis Factor-alpha metabolism, fas Receptor metabolism
- Abstract
Background and Objectives: Normal B-cells in the germinal center (GC) may be exposed to both tumor necrosis factor-related apoptosis inducing ligand (TRAIL) and Fas-L. Whether abrogation of TRAIL apoptosis is a feature in the genesis of B cell lymphomas of GC-phenotype is not known. We assessed the integrity of the TRAIL pathway in Fas-resistant and Fas-sensitive Burkitt s lymphomas (BLs)., Design and Methods: Expression of TRAIL receptors was determined by flow cytometry and Western blots. The extent of apoptosis following exposure to TRAIL was measured by annexin-V/propidium iodide dual staining. The integrity of the Fas and TRAIL apoptotic pathways was determined by Western blotting to assess cleavage of downstream caspases. Western blot analyses were used to determine the expression of pro- and anti-apoptotic proteins and the profile of expression was correlated with response to TRAIL and CH11., Results: Our results demonstrate that BL expresses both functional and decoy TRAIL receptors. BLs with a functional Fas pathway retained sensitivity to TRAIL: Frequent and compound loss of expression of pro-apoptotic proteins can be identified in BLs resistant to Fas. However, loss of Bax, Bak and Bcl-Xs did not compromise sensitivity to TRAIL:, Interpretation and Conclusions: Our results indicate that BLs frequently retain sensitivity to the TRAIL pathway. These results underscore the utility of TRAIL-based therapeutic strategies in the treatment of those B-cell lymphomas that may have compromised expression of several pro-apoptotic proteins.
- Published
- 2003
9. Bcl-6 p53 mutations in lymphomas carrying the bcl-2/Jh rearrangement.
- Author
-
Bellido M, Capello D, Altés A, Estivill C, Gaidano G, Pujol R, Bordes R, Baiget M, Saglio G, Sierra J, and Nomdedéu JF
- Subjects
- Adult, Aged, Chromosomes, Human, Pair 14 genetics, Chromosomes, Human, Pair 18 genetics, DNA Mutational Analysis, Gene Expression Regulation, Neoplastic, Humans, Middle Aged, Proto-Oncogene Proteins c-bcl-6, Survival Rate, DNA-Binding Proteins genetics, Genes, bcl-2 genetics, Lymphoma, Follicular genetics, Mutation genetics, Proto-Oncogene Proteins genetics, Proto-Oncogene Proteins c-bcl-2 genetics, Transcription Factors genetics, Translocation, Genetic genetics, Tumor Suppressor Protein p53 genetics
- Abstract
Background and Objectives: The t(14;18)(q32;q21) chromosomal translocation is the hallmark of follicular lymphomas (FL). The translocation induces the overexpression of the Bcl-2 protein and prolongs the survival of clonogenic cells. Tumor cells may acquire additional molecular alterations that may be associated with histologic progression or with chemo-resistance., Design and Methods: We analyzed the distribution and association of bcl-6 and p53 mutations in 55 consecutive bcl-2/Jh+ lymphoma samples derived from 43 patients obtained at the time of diagnosis and, in 5 of these patients, during follow-up. A total of 29 bcl-6 point mutations were detected in seventeen patients (40%) associated with major or minor breakpoints of the bcl-2/Jh fusion gene. In seven cases a p53 mutation was detected. Three cases corresponded to FL with the minor breakpoint in the bcl-2 gene and these patients had a favorable clinical evolution, whereas the 4 patients with p53 mutations and the major breakpoint had a bad clinical outcome with morphologic transformation to high-grade lymphoma in three cases. The sequential analysis of 5 patients showed a different timing in the acquisition of mutations: one patient showed bcl-6 and p53 mutations at diagnosis, another patient showed bcl-6 mutations at diagnosis and acquired a p53 mutation later whereas the third patient had a p53 mutation before the appearance of the bcl-6 mutation., Results: We did not find significant differences in survival between patients with FL who showed exclusively bcl-6 mutations and those without bcl-6 mutations, but those patients with a high International Progostic Index score and p53 mutations showed the lowest overall survival (p = 0.002)., Interpretation and Conclusions: These findings suggest that bcl-2/Jh lymphomas show molecular heterogeneity and that bcl-6 and p53 mutations may be acquired during the evolution of such lymphomas. Bcl-6 mutations, by themselves, do not seem to be associated with a bad prognosis. Rearrangements at the minor bcl-2 locus may have a different molecular evolution.
- Published
- 2002
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.